Three Diabetes Drugs Linked to Ketoacidosis, FDA Warns
(MedPage Today) -- FDA targets SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Canagliflozin | Cardiology | Cardiovascular | Dapagliflozin | Diabetes | Empagliflozin | Endocrinology | Forxiga | Heart | Invokana | Jardiance | SGLT2 Inhibitors